Lawrence Shao-Liang Liu
Lawrence is the Chairman of CDIB Venture Capital, CDIB Capital Creative Industries Ltd., and CDIB Capital Healthcare Ventures.
Lawrence holds a doctoral degree in law from the University of Chicago and practiced law for over twenty years. He is a board director at Taiwan Stock Exchange, HIM International Music, and CECI Engineering Consultants. He is the chairman of the Financial Holding Business Committee of the Bankers Association of R.O.C., the vice chairman of Taiwan Mergers & Acquisitions and Private Equity Council, a board member of Asia Pacific Cultural and Creative Industrial Association, the vice chairman of Taiwan Venture Capital Association, and the vice chairman of Taiwan Private Equity Association.
Lawrence was chief strategy officer of CDF, president of CDIB, acting chairman for Grand Cathay Securities, chairman of China Venture Management, R.O.C. Strategic Company and CDIB Strategic Venture Fund, independent director to China Airlines, frequent participant of OECD’s Asian Roundtable on Corporate Governance, advisor to the delegation to APEC’s leader and ministerial meetings, and the Executive Director of the Asia-Pacific Regional Operations Center at the Council for Economic Planning and Development under the Executive Yuan. In these capacities, he helped draft a number of financial laws and policies for Taiwan.
Ta-Cheng has participated in the establishment of CDIB Capital Healthcare Ventures since 2012, and is currently acting as president. He is in charge of planning, construction and management of the fund portfolio.
Ta-Cheng has a bachelor degree from the Department of Industrial Engineering of National Tsing Hua University in Taiwan and a master degree in accounting from the University of Missouri-Columbia (US). After graduation, he worked at KPMG as an auditor for nearly two years and became a certified public accountant in Taiwan. He used to be investment manager at Central Investment Holding. He then served as senior vice president at China Trust Venture Capital. In 2004, he became the senior vice president at CDIB. Overall, he has over twenty years of experience in venture capital sector.
Ta-Cheng has acted as a director or supervisor for TWi, JHL Biotech, Axiomtek, RT-Mart, and Acme Electronics. He is currently a director or supervisor for Chunghwa Chemical Synthesis & Biotech and Global BioPharma.
Hsu-Sheng has participated in the establishment of CDIB Capital Healthcare Ventures since 2012. He is currently vice president of CDIB Capital Healthcare Ventures.
Hsu-Sheng graduated from the Department of Economics and the Graduate Institute of Business Administration of National Taiwan University. He has worked at CDIB for nineteen years since graduation, having served in various departments: securities brokerage, overseas investment and domestic investment. He is familiar with structural planning, industrial analysis and financial analysis related to investment business. He has years of experience helping invested companies conduct capital planning and IPOs applications.
Hsu-Sheng is currently the board director to Paonan Biotech and Taihan Precision Technology. He used to be board director or supervisor at K Laser Technology, Alpha Imaging Technology, Solteam Electronics, T-Mac Techvest PCB and Pixon Technologies.
Yi-jiun has participated in the establishment of CDIB Capital Healthcare Ventures since 2012. He is currently vice president of CDIB Capital Healthcare Ventures.
Yi-jiun received his bachelor degree in Information Management and M.B.A. degree from National Taiwan University. After graduation, he went to work for CDIB’s credit and research department and was responsible for industrial research, company credit reporting, and investment analysis. He then moved to the principal investment department to develop, manage, and execute investment projects. He has twelve years of experience being involved in venture capital and industrial investment affairs. While working for CDIB, he was involved in large-scale investment projects such as power plants, leveraged buyouts (LBO) in the cable TV industry, and investment in the steel industry. He specializes in investment analysis, capital planning and project investment framework design for sectors such as energy, pharmaceuticals and medical devices.
Yi-jiun was a board director for Aprevent Medical and Lotus Pharmaceutical. He is now a director at AspirEx Medical Ltd.
Sonia Hsin-Fang Wu
Sonia is vice president of CDIB Capital Healthcare Ventures and focuses on venture capital investing in Greater China related biomedical opportunities.
Sonia holds a MBA and a Bachelor of Science in Chemical Engineering from National Taiwan University. She has fourteen years of experience in venture capital and private equity investment. Prior to CDIB Capital Healthcare Ventures, she was vice president at Principal Investment Department of CDIB and specialized in biotech & healthcare, consumer & retail, software & internet, and China-based industrial manufacturing sectors.
Sonia serves on the board of Foresee Pharmaceuticals (6576.TT), Handa Pharmaceuticals, CVie Therapeutics and SunFun Info (5278.TT).